Orange Book product · Generic (ANDA)
ERIBULIN MESYLATE
ERIBULIN MESYLATE
At a glance
Apr 05, 2024
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 05, 2024
2 yr 3 mo ago
Today
Pharmaceutical detail
Active ingredient
ERIBULIN MESYLATE
Strength
1MG/2ML (0.5MG/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
AP
Application
ANDA 218047
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of ERIBULIN MESYLATE
- 2010HALAVENBrand (NDA)
NDA 201532 · EISAI INC
- 2026ERIBULIN MESYLATEGeneric (ANDA)
ANDA 217085 · NATCO
- 2026ERIBULIN MESYLATEGeneric (ANDA)
ANDA 219054 · XGEN PHARMS
- 2025ERIBULIN MESYLATEGeneric (ANDA)
ANDA 218142 · GLENMARK PHARMS
- 2025ERIBULIN MESYLATEGeneric (ANDA)
ANDA 217473 · DR REDDYS
- 2025ERIBULIN MESYLATEGeneric (ANDA)
ANDA 214310 · SANDOZ
- 2025ERIBULIN MESYLATEGeneric (ANDA)
ANDA 218743 · CHIA TAI TIANQING
- 2024ERIBULIN MESYLATEGeneric (ANDA)
ANDA 217250 · BAXTER HLTHCARE CORP
- 2024ERIBULIN MESYLATEGeneric (ANDA)
ANDA 214850 · LONG GROVE PHARMS
- 2024ERIBULIN MESYLATEGeneric (ANDA)
ANDA 218281 · JIANGXI KVVIT PHARM
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
